Nano-X Imaging Ltd.

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company develops a prototype of the Nanox.ARC, a medical imaging system incorporating its digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that would allow for the delivery of medical screening as a service. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company was founded in 2011 and is headquartered in Neve Ilan, Israel.

Nanox Vision develops a next-generation medical imaging system based on groundbreaking technology. Our aim is to democratize medical imaging and bring preventive healthcare to communities worldwide, helping create a better standard of care for all.

SK Square Americas

SK Telecom

Foxconn Technology Group

Fujifilm

Yozma Group

Foxconn

Industrial Alliance Insurance and Financial Services

Nanox Vision

This #BlackHistoryMonth, we are raising awareness to disparities in healthcare, which includes limited access to medical imaging. We are proud to take on this challenge by developing solutions that improve access to imaging and ultimately improve patient outcomes. 
 
#HealthEquity

Many people experience stress and anxiety when preparing for medical imaging. This is known as radiophobia. Fortunately, the sleek and open design of the Nanox.ARC may help with that.  
  
Discover more: https://lnkd.in/ecXjXF7r  
   
#medicalimaging #anxiety #healthcare #NanoxARC

In honor of International Women & Girls in Science Day, we want to thank our #WomeninSTEM colleagues for their amazing contributions to Nanox, our community and the scientific world! 
#February11 #WomeninScience

Nanox.ARC a 3D, multi-source, advanced digital tomosynthesis imaging system, addresses key issues that have previously hindered access to tomosynthesis-based platforms, providing anatomy visualization with multiple layers of images. 
 
Learn more about the advantages offered by the Nanox.ARC: https://lnkd.in/ecXjXF7r 

#NanoxARC #medicalimaging

🌍 Exciting Milestone Achieved in Sub-Saharan Africa! 🌟


We at Forte Medical are thrilled to share a momentous achievement as we successfully conducted the first patient scan on the Nanox.ARC at the University of Ghana Medical Centre! This marks a significant leap towards revolutionizing healthcare accessibility in Sub-Saharan Africa. 

Our collaboration with Nanox Vision  and University of Ghana Medical Centre LTD  exemplifies our shared vision of creating access to quality and affordable healthcare for all. 

As we take this pioneering step, we look forward to introducing more groundbreaking technologies that will reshape the healthcare landscape in the region.

Stay tuned as we embark on this transformative journey, advancing healthcare one milestone at a time! 💙🌐
 
#HealthcareInnovation #MedicalTechnology #SubSaharanHealthcare #NanoxARC #QualityHealthcare #TransformingHealthcare

NASDAQ:NNOX

Nano-X Imaging Ltd.

Last Close

6.14

25/09 14:39

Market Cap

447.21M

Beta: 1.81

Volume Today

136.76K

Avg: 1.49M

PE Ratio

−3.20

PFCF: −6.40

Analysis Not Available